Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited]

The mRNA vaccines from Pfizer/BioNTech and Moderna were granted emergency approval in record time in the history of vaccinology and played an instrumental role in limiting the pandemic caused by SARS-CoV-2. The success of these vaccines resulted from over 3 decades of research from many scientists....

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 13; p. 884862
Main Authors Jawalagatti, Vijayakumar, Kirthika, Perumalraja, Lee, John Hwa
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 03.05.2022
Subjects
alphaviral replicon
Bacteria
bacterial delivery
Communicable Diseases
COVID-19 - prevention & control
COVID-19 Vaccines
Humans
Immunology
mRNA vaccine
mRNA Vaccines
mucosal vaccine
oral
RNA, Messenger - genetics
SARS-CoV-2
SARS-CoV-2 - genetics
Vaccines, Synthetic
SARS-CoV-2
infectious diseases
mucosal vaccine
bacterial delivery
oral
alphaviral replicon
mRNA vaccine
Online AccessGet full text

Cover

More Information
Summary:The mRNA vaccines from Pfizer/BioNTech and Moderna were granted emergency approval in record time in the history of vaccinology and played an instrumental role in limiting the pandemic caused by SARS-CoV-2. The success of these vaccines resulted from over 3 decades of research from many scientists. However, the development of orally administrable mRNA vaccine development is surprisingly underexplored. Our group specializing in -based vaccines explored the possibility of oral mRNA vaccine development. Oral delivery was made possible by the exploitation of the Semliki Forest viral replicon and vehicle for transgene amplification and gene delivery, respectively. Herein we highlight the prospect of developing oral replicon-based mRNA vaccines against infectious diseases based on our recent primary studies on SARS-CoV-2. Further, we discuss the potential advantages and limitations of bacterial gene delivery.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Present addresses: Vijayakumar Jawalagatti, Urology Department, Mayo Clinic, Rochester, MN, United States; Perumalraja Kirthika, Biochemistry and Molecular Biology Department, Mayo Clinic, Rochester, MN, United States
These authors have contributed equally to this work
Edited by: Gabriel Pedersen, Statens Serum Institut (SSI), Denmark
Reviewed by: Irina V. Kiseleva, Institute of Experimental Medicine (RAS), Russia; Bert Devriendt, Ghent University, Belgium; Shankargouda Patil, Jazan University, Saudi Arabia
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.884862